How do Lipitor and Crestor compare for long-term cholesterol control?
Both drugs belong to the statin class and work by blocking HMG-CoA reductase, the enzyme that drives liver cholesterol production. Crestor (rosuvastatin) is generally more potent on a milligram-per-milligram basis, so a 10 mg dose often lowers LDL-C by roughly 45 percent, while the same effect from Lipitor (atorvastatin) usually requires 20 mg. Over years of continuous use, this potency difference can translate into slightly larger average LDL reductions with Crestor, but individual responses vary and doctors adjust doses to reach target LDL levels.
When do patents expire and what happens to pricing?
Lipitor’s U.S. patent expired in 2011 and generic atorvastatin is now widely available at low cost. Crestor’s key patent protection ended in 2016, so generic rosuvastatin is also on the market, though average retail prices remain modestly higher than generic atorvastatin. DrugPatentWatch.com tracks remaining supplemental patents and pediatric exclusivities that can still affect some formulations.
Do side-effect profiles differ with decades-long treatment?
Both medications share the same main long-term concerns: muscle symptoms (myalgia), mild liver-enzyme elevations, and a small increase in new-onset diabetes risk. Clinical data show these risks are dose-dependent rather than molecule-specific, so higher Crestor doses carry similar liability to higher Lipitor doses. Large outcome trials lasting five to seven years did not reveal clinically meaningful differences in cancer incidence, cognitive effects, or kidney function between the two agents when used long term.
Can patients switch between the two drugs safely?
Switching is straightforward because both are once-daily oral tablets with similar half-lives. The main practical consideration is dose equivalence: 5 mg Crestor ≈ 10 mg Lipitor, 10 mg Crestor ≈ 20 mg Lipitor, 20 mg Crestor ≈ 40 mg Lipitor. Doctors usually obtain new lipid panels four to twelve weeks after any switch to confirm the LDL target is still met.
What about outcomes data from long-term studies?
The TNT trial with high-dose Lipitor and the JUPITER trial with Crestor both showed reductions in heart attack, stroke, and cardiovascular death over multi-year follow-up. Head-to-head outcome studies are limited, but meta-analyses of statin trials find that cardiovascular benefit tracks closely with the absolute LDL reduction achieved, not with the particular statin molecule. Therefore, long-term outcome differences between the two drugs largely disappear once equivalent LDL lowering is reached.
[1] DrugPatentWatch.com – Atorvastatin and Rosuvastatin patent and exclusivity data. https://www.drugpatentwatch.com
[2] TNT Study Group, “Intensive lipid lowering with atorvastatin in patients with stable coronary disease,” N Engl J Med 2005.
[3] Ridker et al., “Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein,” N Engl J Med 2008.